Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CAR-T cell, preparation method thereof and medicine

A cell and dead cell technology, applied in the field of cell biology, can solve the problems of large side effects and weak tumor cell killing ability.

Active Publication Date: 2020-08-11
湖南光琇医院有限公司
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, CAR-T cells still have serious side effects in the application, such as causing severe cytokine release syndrome (CRS), and some of them are not strong enough to kill tumor cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CAR-T cell, preparation method thereof and medicine
  • CAR-T cell, preparation method thereof and medicine
  • CAR-T cell, preparation method thereof and medicine

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0039] The present invention relates to a preparation method of CAR-T cells, comprising the following steps:

[0040] (1) Inoculate T cells in CAR-T medium and culture for 18-24 hours;

[0041] (2) introducing the vector carrying the chimeric antigen receptor sequence and the puromycin resistance gene into the cells obtained in step (1), and culturing for 18 to 24 hours;

[0042] (3) Collect the cells obtained in step (2) with 0.5~1×10 6 Cell density per ml was inoculated in CAR-T medium and cultured for 36-48 hours;

[0043] (4) Collect the cells obtained in step (3) with 0.5~1×10 6 Cell density per ml was inoculated in CAR-T medium, and puromycin was added, and cultured for 36-48 hours;

[0044] (5) Collect the cells obtained in step (4) and remove the dead cells therein, with 0.5~1×10 6 Cell density per ml was inoculated in CAR-T medium, and puromycin was added, and cultured for 36-48 hours to obtain CAR-T cells.

[0045] In the past studies, CAR-T cells cultured for 8...

Embodiment 1

[0056] Example 1 (d8pCAR-T)

[0057] Obtain 10mL peripheral whole blood from healthy donors or leukocyte apheresis to obtain leukocyte collection, use the kit RosetteSep Human T Cells enrichment cocktail from STEMCELL Technologies, operate according to the instructions, separate from peripheral whole blood or leukocyte collection with a purity of More than 99% of CD3+ T cells are frozen in liquid nitrogen or used directly.

[0058] D0 day: Take a certain amount of CD3+ T cells, use CAR-T medium (serum-free medium + 3% CTS TM ImmuneCell SR + 1% non-essential amino acid + 1% HEPES + 1% sodium pyruvate + 1% streptomycin-penicillin + 1% GlutaMAX + 100Unit / ml IL-2) for culture, and add Invitrogen's magnetic beads Dynabeads Human For T-Activator CD3 / CD28, the adding ratio is the number of cells: the number of magnetic beads = 2:1. at 37°C, 5% CO 2 Cultivate in an incubator for 18h to 24h.

[0059] Day D1: Use TAKARA's fibronectin solution to coat a six-well culture plate at room...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a CAR-T cell, a preparation method thereof and a medicine. Negative T cells which fail to transduce CAR genes are removed through culture and purification operation of specific steps, T cells with puromycin resistance genes are reserved, and the proportion of CAR positive T cells is greatly increased. More importantly, experimental comparison shows that although the culture time of the CAR-T cells obtained through culture and purification operation of the specific steps is prolonged, the side effects of the CAR T cells in application are remarkably reduced, for example, the secretion level of inflammatory cytokines IL-6 and other proinflammatory related cytokines is reduced; Th17 cell subgroup components are reduced, and IL-17 / IL-17A secretion is reduced; anti-inflammatory related cytokine secretion is increased; and the killing capacity on tumor cells in vitro and in mice is greatly enhanced, and the survival time of the mice is prolonged.

Description

technical field [0001] The invention relates to the technical field of cell biology, in particular to a CAR-T cell, a preparation method and a medicine thereof. Background technique [0002] Chimeric Antigen Receptor T cell (CAR-T) therapy, which is a new type of precise targeted therapy for tumor treatment, has achieved good results in clinical tumor treatment through optimization and improvement in recent years. It is a very promising new tumor immunotherapy method that is accurate, fast, efficient, and has the potential to cure cancer. T cells, also called T lymphocytes, are a type of human white blood cells, derived from bone marrow hematopoietic stem cells, mature in the thymus, and then migrate to human blood, lymph and surrounding tissues and organs to exert immune functions. It can resist pathogenic infection, remove tumors, foreign bodies, etc. The chimeric antigen receptor (CAR) is introduced into human T cells through genetic engineering technology to obtain CAR...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/867C12N5/10A61K39/00A61P35/00
CPCC12N15/86C12N5/0636A61K39/0011A61P35/00C12N2740/15043C12N2510/00A61K2039/5156A61K2039/5158
Inventor 卢光琇林戈陈濂生易辉君郝建军周英邵梦思罗孝宇吴静
Owner 湖南光琇医院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com